Myths and misbelieves regarding COVID vaccines in India
Keywords:COVID-19, COVID vaccination, Vaccine adverse effects, vaccine beneficiaries, Cross sectional Study
Background: - COVID-19 is the most important public health problem of recent time. Many people require hospitalization after infection. COVID vaccination is the most effective way to prevent the disease. Due to extensive negative publicity through social media channels/platforms,significant number of individuals are not coming forward for vaccination. Therefore, study is needed to evaluate adverse effects associated with different vaccines available in India. Objectives: - To assess the adverse effects associated with COVID-19 vaccination and compare the side effect of two most commonly used COVID vaccines in India. Methods:- In the current report, a cross sectional study was conducted among beneficiaries of COVID-19 vaccines at the vaccination center of the LLRM Medical college, India. After institutional ethical clearance and informed consent, patients were asked about the symptoms they experienced after vaccination. A very simple random sampling approach was used to select beneficiaries. Information was collected on predesigned Google form and total 391 patients submitted the responses. Results:- Out of total respondents 77 % individuals reported one or more symptoms. Fever was reported to be most common problem (59.3%) followed by body ache (57.5%). Out of total beneficiaries, 68.3% experienced mild symptoms while 23% remain asymptomatic. Only few subjects reported moderate adverse effects (8.7%). None of the respondent reported severe and serious adverse effect. Conclusions:- Vaccine associated adverse effects were found less than 3 days and of mild variety in most of the beneficiaries. There was no difference in adverse effect profile of two commonly used vaccines in India. People must come forward for vaccination in mass without fearing of adverse effects of vaccines.
Ministry of Health and Family Welfare, Government of India. Available from https://www.mohfw.gov.in. (Accessed on 20.03.2022).
World Health Organization. Novel Coronavirus (2019-nCoV) Situation Report – 1. 21 JANUARY 2020. Available from https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf. (Accessed on 20.03.2022)
World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19–11 March 2020. Available from https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-COVID-19---11-march-2020. (Accessed on 20.03.2022)
Sahil Loomba, Alexandre de Figueiredo, Simon J. Piatek, Kristen de Graaf & Heidi J. Larson Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA Nature Human Behaviour volume 5, pages337–348 (2021). Available from https://www.nature.com/articles/s41562-021-01056-1. (Accessed on 20.03.2022)
Ministry of Health and Family welfare. An Illustrated Guide on COVID Appropriate Behaviour – MoHFW. Available from https://www.mohfw.gov.in › pdf › Illustrativeguidelines . (Accessed on 20.03.2022)
World Health Organization. Newsroom 2021. Available from https://www.who.int/news-room/feature-stories/detail/the-race-for-a-COVID-19-vaccine-explained. (Accessed on 20.03.2022)
Ministry of Health and Family Welfare, Government of India. COVID-19 Vaccination. Available from https://www.mohfw.gov.in/pdf/COVID19VaccinationGuideforHealthcareandFrontlineWorkers.pdf . (Accessed on 20.03.2022)
World Health Organization. Newsroom. World Health Organization. Newsroom 2021. WHO lists Moderna Vaccine for modern use. Available from https://www.who.int/news/item/30-04-2021-who-lists-moderna-vaccine-for-emergency-use. (Accessed on 20.03.2022)
Datareportal. Digital 2021: India. Available from https://datareportal.com/reports/digital-2021 -india#:~:text=There%20were%20624.0%20million%20internet,at%2045.0%25%20in%20January%202021. (Accessed on 20.03.2022)
The Print. Oxford and Covaxin to Sputnik V –the many COVID vaccines in trial and how they are faring . Available from https://theprint.in/health/oxford-and-covaxin-to-sputnik-v-the-many-COVID-vaccines-in-trial-how-theyre-faring/500909/. (Accessed on 20.03.2022)
Yale School of Medicine. Sex and Gender and COVID-19 vaccine side effects. Available from https://medicine.yale.edu/news-article/sex-and-gender-and-COVID-19-vaccine-side-effects/ . (Accessed on 20.03.2022)
MOSTAFA A. 2019 Novel Coronavirus Vaccination among Post-graduate Residents and Fellows. Available from https://doi.org/10.1177/21501327211022978. (Accessed on 20.03.2022)
World Health Organization. Side effects of COVID-19 vaccines. Available from https://www.who.int/news-room/feature-stories/detail/side-effects-of-COVID-19-vaccines. (Accessed on 20.03.2022)
Ministry of Health and Family Welfare. COVID Vaccination. Available from https://www.mohfw.gov.in/COVID_vaccination/vaccination/common-side-effects-aefi.html . (Accessed on 20.03.2022)
Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C., Nguyen, L., Drew, D., Merino, J., Hu, C., Selvachandran, S., Antonelli, M., Murray, B., Canas, L., Molteni, E., Graham, M., Modat, M., Joshi, A., Mangino, M., Hammers, A., Goodman, A., Chan, A., Wolf, J., Steves, C., Valdes, A., Ourselin, S. and Spector, T., 2021. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious Diseases, [online] 21(7), pp.939-949. Available from: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00224-3/fulltext. (Accessed on 20.03.2022).
Times of India. India News. Majority Indians experienced no or mild side effects post 2 doses of Covishield and Covaxin: Report. Available from https://timesofindia.indiatimes.com/india/majority-indians-experienced-no-or-mild-side-effects-post-2-doses-of-covishield-and-covaxin-report/articleshow/85645749.cms. (Accessed on 20.03.2022)
How to Cite
Copyright (c) 2022 Indian Journal of Community Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.